B. Riley lowered the firm’s price target on IperionX (IPX) to $28 from $30 and keeps a Buy rating on the shares. IperionX is scaling up titanium manufacturing at its Virginia campus, with full operational capacity expected by mid-2025, although Riley now assumes a more conservative ramp, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IPX:
- IperionX Ltd. Announces Director’s Share Acquisition
- IperionX commences DFS for Titan Critical Minerals Project
- IperionX Launches Feasibility Study for Titan Project with U.S. Government Support
- IperionX receives approval for $11M equipment finance loan
- IperionX Ltd. ADR: Advancing U.S. Titanium Supply Chain